Luis Oliverio Ambriz Garcia/X
Aug 27, 2026, 07:19
Luis Oliverio Ambriz Garcia: ASH 2026 Guidelines – What’s New in ITP?
Luis Oliverio Ambriz Garcia, Doctor, Specialist in Internal Medicine at HRAEB, Chief Executive Officer of Memodi, shared a post on X:
“The new American Society of Hematology (ASH, 2026) guidelines for Immune Thrombocytopenia.
Some key points and changes:
- First-line therapy: no longer steroids alone. Rituximab plus steroid or Thrombopoietin Receptor Agonists (TPO-RAs – such as Eltrombopag) plus steroid are suggested.
- Second-line therapy: Thrombopoietin Receptor Agonists (TPO-RAs). Order: TPO-RA then rituximab, then BTKi/MMF/SYKi, then azathioprine.
- Splenectomy: defer for greater than or equal to 1 year, vaccinate greater than or equal to 2 weeks prior, annual follow-up.
- Dosage: steroids for less than or equal to 6 weeks always; dexa 40 mg for 4 days (1–3 cycles) or prednisone 0.5–2 mg/kg/day; rituximab 375 mg/m² for 4 weeks.”
Stay updated with Hemostasis Today.
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE